Different Funding Opportunities
NIDA offers a broad range of funding opportunities that target all stages of biomedical product development (Ideation, Feasibility, and Product Development). To help companies develop their innovative ideas, NIDA participates in the:
- The SBIR and STTR omnibus solicitation. This funding opportunity targets PI-initiated research (your own idea) that has the potential for technology commercialization and impact on public health.
- NIDA-specific SBIR and STTR Targeted Notices of Funding Opportunities (NOFOs). The funding opportunity outlines a specific problem that needs to be addressed and invites companies to present their possible solutions. The solicitation can come in the form of a grant through a Request for Applications (RFAs) or a contract through a Request for Proposals (RFP). A contract mechanism is used when the solution attributes are more clearly defined and there is a specific solution to the problem, compared to a grant mechanism where there are multiple possible solutions to the problem.
View funding opportunities with budget and application due date details.
Required Registrations
To apply for these funding opportunities, a company must complete five required registrations. Registrations are free and the process can take 6-8 weeks, so it is important to begin the registration process as early as possible. All registrations must be completed prior to the submission of an application:
- DUNS – required to obtain a unique organization identifier
- SAM (System for Award Management) – required to do business with the U.S. government.
- eRA Commons – required to submit grant applications through the federal-wide portal.
- Grants.gov – required to submit grant applications through the federal-wide grant portal.
- SBA (Small Business Administration) – required to participate in SBIR and STTR federal funding programs.
Additional details about each registration can be found on the NIH SEED site.
There are multiple ways to apply to NIH, including ASSIST, a web-based application.